The present invention relates to the use of inhibitors of the expressed proteins of TCF target genes whose expression is regulated by TCF/.beta.-catenin complexes for the preparation of a therapeutical composition for the treatment of cancers in which TCF/.beta.-catenin signalling is deregulated. Such inhibitors can be antibodies, small molecules, antisense RNA and dsRNA for use in RNAi. The invention also relates to these inhibitors per se.
|Publication status||Published - 2006|
Bibliographical noteUnited States Patent 20060165699; http://www.freepatentsonline.com/20060165699.html
Colland, F., Barker, N., Clevers, J. C., Gomez, E., Lambertus, M., & Suils, E. S. (2006). Use of specified tcf target genes to identify drugs for the treatment of cancer in particular colorectal cancer in which tcf/ss-cateini/wnt signalling plays a central role.